Edition:
United Kingdom

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

9.66USD
22 Feb 2018
Change (% chg)

$0.15 (+1.58%)
Prev Close
$9.51
Open
$9.57
Day's High
$9.81
Day's Low
$9.55
Volume
32,215
Avg. Vol
55,138
52-wk High
$17.33
52-wk Low
$7.92

Chart for

About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on... (more)

Overall

Beta: --
Market Cap(Mil.): $482.91
Shares Outstanding(Mil.): 40.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Seres Therapeutics Says Has Cash, Cash Equivalents And Investments Of $171.3 Mln

* SERES THERAPEUTICS SAYS HAS CASH, CASH EQUIVALENTS AND INVESTMENTS OF $171.3 MILLION, AS OF SEPT 30, 2017 - SEC FILING Source text: (http://bit.ly/2qFSBN0) Further company coverage:

08 Jan 2018

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

04 Dec 2017

Earnings vs. Estimates